Thor Medical

Mindre end 1K følgere

TRMED

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Investorkonsensus

Thor Medical is a manufacturer and supplier of alpha particle emitters for cancer treatment. Radionuclide therapy (RNT) or radioligand therapy (RLT) using alpha particle emitters is a promising technology for cancer treatment. The main focus of the company is to refine the production technology, secure the customer base and necessary regulatory approvals for industrialization. Thor Medical is headquartered in Oslo.

Markedsværdi

-

Aktieomsætning

-

Omsætning

400 t

EBIT %

-17.425 %

P/E

-

Udbytteafkast, %

-

Finanskalender

23.4

2026

Generalforsamling '26

28.8

2026

Delårsrapport Q2'26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse13.3.2026, 09.19

Thor Medical ASA - New share capital registered

Selskabsmeddelelse2.3.2026, 18.41

Thor Medical ASA - Completed primary insider purchases after option exercise

Selskabsmeddelelse27.2.2026, 09.39

Thor Medical ASA - Exercise of share options and resolution to increase share capital

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse26.2.2026, 06.00

Thor Medical ASA: Second-Half and Full-Year 2025 Results - AlphaOne on Track, Backed by Strong Commercial Momentum

Selskabsmeddelelse18.2.2026, 06.00

Thor Medical ASA: Invitation to Presentation of Second-Half and Full-Year 2025 Results

Selskabsmeddelelse6.1.2026, 07.52

Thor Medical - Issuance of shares to executive member under incentive program

Selskabsmeddelelse23.12.2025, 07.00

TRMED: Thor Medical reaches key construction milestones at AlphaOne plant

Selskabsmeddelelse4.12.2025, 07.00

TRMED: RadioMedix and Thor Medical enter supply agreement for thorium-228

Pressemeddelelse28.11.2025, 07.39

BioStock: Thor Medical advances toward commercial scale following pilot success and major deal streak

Selskabsmeddelelse20.11.2025, 12.27

Thor Medical ASA - New share capital registered

Selskabsmeddelelse20.11.2025, 06.30

TRMED: Thor Medical enters supply agreement with NucliThera for thorium-228

Selskabsmeddelelse18.11.2025, 06.30

TRMED: Thor Medical strengthens executive team to realise leadership ambitions in targeted alpha therapies

Selskabsmeddelelse11.11.2025, 22.15

Thor Medical - Issuance of RSU shares to members of the board

Pressemeddelelse7.11.2025, 07.14

BioStock: Thor Medical comments on the Telix agreement

Selskabsmeddelelse6.11.2025, 06.30

TRMED: Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thorium-228

Selskabsmeddelelse29.8.2025, 05.15

Thor Medical ASA interim results for 1H 2025 - strong operational and commercial progress

Selskabsmeddelelse29.8.2025, 05.00

TRMED: Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement

Selskabsmeddelelse22.8.2025, 06.00

Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at 08:00

Selskabsmeddelelse4.8.2025, 05.30

TRMED: Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228

Selskabsmeddelelse1.8.2025, 06.58

Thor Medical ASA - Share capital increase in relation to Subsequent Offering is registered

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.